Clairity has received FDA de novo authorization for Clarity Breast, an AI tool that predicts five-year breast cancer risk from screening mammograms.
Key Details
- 1Clairity Breast predicts future breast cancer risk using AI analysis of 2D screening mammograms.
- 2FDA de novo authorization has been granted for the software platform.
- 3The AI model was trained on 450,000+ mammograms and validated on 77,000 exams with five-year follow-up data.
- 4Unlike CAD tools, the software provides a risk percentage for patients rather than assisting real-time interpretation.
- 5Models were developed for diverse populations, addressing historic limitations in risk prediction for non-European ancestry.
- 6Currently available for Hologic mammography systems, with future plans for multivendor and 3D support.
Why It Matters
This represents a significant advance in leveraging mammogram images beyond immediate diagnosis, opening new avenues for personalized risk assessment in breast imaging. The FDA clearance and focus on diversity in model training mark meaningful steps toward broader clinical adoption and equity.
Source
AuntMinnie
Related News
•Health Imaging
AI Detects Incidental Lung Nodules on Routine Chest X-Rays
AI can identify pulmonary nodules on chest X-rays, aiding early lung cancer detection even when scans are not respiratory-related.
•AuntMinnie
How Agentic AI Is Transforming Imaging Interoperability
Agentic AI can automate complex, non-standard tasks in imaging interoperability, reducing manual work and improving efficiency.
•AuntMinnie
AI in Breast Imaging Achieves High NPV but Raises Recall Rates
AI systems in breast imaging yield near-perfect negative predictive value but increase recall rates compared to radiologists, particularly for intermediate-risk classifications.